Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers

Healthy Clinical Trial

Official title:

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02106247
• Other study ID #: 1344.20
• Secondary ID: 2013-004563-32
• Status: Completed
• Phase: Phase 1
• First received: April 1, 2014
• Last updated: July 9, 2014
• Start date: April 2014
• Est. completion date: June 2014

Study information

• Verified date: July 2014
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal and Health Products
• Study type: Interventional

Clinical Trial Summary

To assess the reduction of ß-amyloid levels in cerebrospinal fluid and plasma and to evaluate pharmacokinetics, safety and tolerability following single oral doses of BI 1181181.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion criteria:

1. Healthy males according to the investigator´s assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests

2. Age 18 to 50 years (incl.)

3. BMI 18.5 to 29.9 kg/m2 (incl.)

4. Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria:

1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and judged clinically relevant by the investigator

2. Repeated measurement of systolic blood pressure < 90 mmHg and >= 140 mmHg at screening in supine position

3. Repeated measurement of diastolic blood pressure < 55 and >= 90 mmHg at screening in supine position

4. Repeated measurement of pulse rate < 40 bpm and > 90 bpm at screening

5. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance

6. Any evidence of a concomitant disease judged clinically relevant by the investigator

7. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders

8. Surgery of the gastrointestinal tract that could interfere with kinetics of the trial drug

9. Diseases of the central nervous system (such as epilepsy), other neurological disorders or psychiatric disorders

10. History of relevant orthostatic hypotension, fainting spells, or blackouts

11. Chronic or relevant acute infections

12. Positive testing on infectious diseases

13. History of relevant allergy/hypersensitivity (including allergy to the trial medication or its excipients)

14. Intake of drugs with a long half-life (>24 hours) within 30 days or less than 10 halflives of the respective drug prior to administration of trial medication

15. Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial

16. Participation in another trial with investigational drug administration within 60 days prior to administration of trial medication

17. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)

18. Inability to refrain from smoking on trial days

19. Alcohol abuse (consumption of more than 40 g per day)

20. Drug abuse

21. Positive testing in the alcohol breath test or the drug screening test

22. Blood donation (more than 100 mL within 30 days prior to administration of trial medication or during the trial)

23. Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial

24. Inability to comply with dietary regimen of trial site

25. At screening, a marked baseline prolongation of QT/QTc interval (such as repeated demonstration of a QTcF interval >450 ms) or any other relevant ECG finding

26. A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)

27. Abnormal parameters for thyroid hormones (T3, T4, TSH), coagulation parameters (partial thromboplastin time (aPTT), prothrombin time (PT) and fibrinogen (retests prior inclusion are allowed))

28. Subject is assessed by the investigator as unsuitable for inclusion, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

29. Male subjects who do not agree to minimize the risk of female partners becoming pregnant from the first dosing day until two month after the trial completion. Acceptable methods of contraception comprise barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive for at least two month prior trial participation)

30. History of retinopathy

31. Any history or present disease of the central nervous system, the spinal cord or the spinal column, which could provoke complications with procedure of the lumbar catheterization/intrathecal punction

32. Signs of intracranial overpressure as determined by funduscopy

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• BI 1181181 high dose
two tablet
• BI 1181181 low dose
one tablet
• Placebo
tablet

Locations

Country	Name	City	State
Belgium	1344.20.32001 Boehringer Ingelheim Investigational Site	Antwerpen

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	%-change from baseline of Aß1-40 in cerebrospinal fluid at the end of the dosing interval (i.e., 24 hrs post dose) (PoM)		up to 24 h	No
Secondary	AUC0-tz (area under the concentration-time curve of the analyte in plasma and cerebrospinal fluid over the time interval from 0 to the last quantifiable data point)		up to 72 h	No
Secondary	Cmax (maximum measured concentration of the analyte in plasma and cerebrospinal fluid)		up to 72 h	No
Secondary	AUC0-infinity (area under the concentration-time curve of the analyte in plasma and cerebrospinal fluid (if possible) over the time interval from 0 extrapolated to infinity)		up to 72 h	No